MUP1 Antibody

What is MUP1 and what are its primary biological functions?

MUP1 (Major Urinary Protein 1) is a 20 kDa lipocalin family glycoprotein primarily secreted by the liver into circulation and subsequently excreted in the urine, particularly in male mice. The protein features a beta-barrel structure with an internal hydrophobic cavity that enables it to function as a carrier for various pheromones .

Beyond its pheromone-carrying capacity, MUP1 plays crucial roles in metabolic regulation. It promotes energy expenditure, mitochondrial biogenesis, and oxidative function. Additionally, it inhibits hepatic glucose production, triglyceride accumulation, glucose intolerance, and insulin resistance. Notably, MUP1 is downregulated in the liver and circulation of diabetic obese mice, suggesting its importance in metabolic homeostasis .

In experimental models, MUP1 has been shown to directly regulate glucose metabolism by suppressing gluconeogenic programs in the liver. When overexpressed in diabetic mouse models (db/db mice), MUP1 significantly reduces blood glucose levels and improves glucose tolerance .

How should MUP1 antibodies be stored and handled for optimal performance?

For optimal antibody performance, implement the following storage and handling protocols:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain antibody integrity

• Store at -20 to -70°C for up to 12 months from the date of receipt (as supplied)

• After reconstitution, antibody remains stable for approximately 1 month at 2 to 8°C under sterile conditions

• For long-term storage after reconstitution, store at -20 to -70°C under sterile conditions for up to 6 months

When preparing working solutions, ensure sterile technique and use appropriate buffer conditions that maintain protein stability. Document all freeze-thaw cycles and monitor performance with appropriate positive controls before use in critical experiments.

What are the validated applications for MUP1 antibodies in research?

MUP1 antibodies have been validated for several experimental applications, including:

• Immunocytochemistry (ICC): Successfully used to detect MUP1 in fixed NCTC 1469 mouse liver cell lines

• Immunoblotting (Western blot): Effective for detecting both cellular and secreted forms of MUP1 in various tissues and biological fluids

• Metabolic studies: Used to trace MUP1 expression changes in relation to metabolic disorders

When performing ICC, optimal results have been achieved using a concentration of 10 μg/mL with an incubation period of 3 hours at room temperature. For visualization, NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody has been effectively used, with DAPI counterstaining to identify nuclei. Using this approach, specific MUP1 staining localizes predominantly to the cytoplasm in liver cells .

How can researchers verify the specificity of MUP1 antibodies in their experimental system?

To ensure antibody specificity for MUP1, implement the following verification procedures:

• Positive and negative controls: Test antibodies on tissues/cells known to express high levels of MUP1 (male mouse liver tissue/hepatocytes) versus those with minimal expression.

• Recombinant expression verification: Generate cells expressing recombinant MUP1 via adenoviral infection, then confirm antibody detection of the protein in both cellular lysates and culture medium (as MUP1 is secreted) .

• Knockout/knockdown validation: Compare antibody signal between wild-type samples and those where MUP1 expression has been genetically reduced or eliminated.

• Cross-reactivity assessment: Test against related MUP family members to ensure specificity, particularly important since multiple MUP isoforms exist with high sequence homology.

• Multiple detection methods: Confirm findings using alternative techniques (qRT-PCR for mRNA expression alongside protein detection) to corroborate results .

How can MUP1 antibodies be utilized to investigate glucose metabolism disorders?

MUP1 antibodies offer valuable tools for investigating glucose metabolism disorders through several methodological approaches:

• Expression analysis in metabolic disease models: Use antibodies to monitor MUP1 protein levels in various metabolic conditions. Research has demonstrated that MUP1 expression is markedly reduced in both genetic (db/db mice) and dietary fat-induced obesity models, suggesting its relevance as a biomarker for metabolic dysfunction .

• Therapeutic intervention assessment: After MUP1 overexpression therapy (via adenoviral delivery), antibodies can be used to confirm increased protein levels in the liver and circulation, correlating with improved metabolic parameters including reduced blood glucose levels and enhanced insulin sensitivity .

• Mechanistic investigations: Antibodies can help elucidate how MUP1 regulates gluconeogenic pathways by examining its effects on key enzymes like G6Pase and PEPCK. In primary hepatocyte cultures, MUP1 overexpression inhibits G6Pase expression by 70% and PEPCK by 54%, demonstrating direct regulation of glucose production .

• In vitro functional studies: Using conditioned medium containing recombinant MUP1 (verified by antibody detection), researchers can assess direct effects on hepatic glucose production in primary hepatocytes, separating cell-autonomous effects from systemic influences .

The following table summarizes key findings on MUP1's effects on metabolic parameters:

What methodological approaches can be used to study MUP1 localization and trafficking?

To effectively investigate MUP1 localization and trafficking, researchers should consider these methodological approaches:

• Combined microscopy techniques: Total internal reflection fluorescence microscopy (TIRFM) combined with 2D deconvolution has proven effective for studying MUP1 localization patterns at the plasma membrane. This approach reveals that MUP1 localizes to specific membrane compartments (MCC - membrane compartment containing Can1) and shows a mixed distribution pattern with weaker staining in network-like structures .

• Quantitative colocalization analysis: Using automated algorithms to analyze thresholded TIRFM images allows for precise measurement of MUP1 colocalization with other membrane domain markers like Pil1. This technique has demonstrated that MUP1 exits the MCC domain upon substrate (methionine) addition .

• Mutational analysis: Truncation mutants (N-terminal, C-terminal) help identify domains responsible for protein trafficking and localization. For example, removing the C-terminus of MUP1 (ΔC = aa520-end) preserves transport activity but prevents ubiquitination and subsequent internalization upon substrate addition .

• Dynamic tracking of relocalization: Time-course imaging after substrate addition or removal can reveal the reversible nature of MUP1 localization changes. This approach has shown that MUP1 clustering in MCC is independent of ubiquitination but its exit from this domain requires specific structural elements .

• Correlation with functional states: By correlating localization patterns with transport activity measurements, researchers can determine how compartmentalization relates to functional states of the transporter.

How should researchers interpret contradictory findings regarding MUP1 in different experimental models?

When confronting contradictory findings regarding MUP1 across different experimental models, consider these methodological approaches:

What are common challenges when working with MUP1 antibodies and how can they be addressed?

When working with MUP1 antibodies, researchers commonly encounter these challenges that can be addressed through methodological adjustments:

• High background in imaging applications:

  • Challenge: Non-specific staining can obscure true MUP1 localization, particularly problematic when studying its subtle redistribution between membrane compartments.

  • Solution: Optimize blocking conditions (3-5% BSA or normal serum from the secondary antibody species), increase washing steps, and validate specificity with appropriate controls including secondary-only samples .

• Signal interference from internalized protein:

  • Challenge: When studying MUP1 membrane localization after substrate addition, strong signal from endosomes with internalized MUP1 can interfere with plasma membrane analysis.

  • Solution: Use internalization mutants (Δart1 background, ΔN or 2KR mutants) that remain at the plasma membrane after substrate addition, allowing clearer visualization of membrane redistribution patterns .

• Distinguishing between MUP family proteins:

  • Challenge: Multiple MUP isoforms share high sequence homology, potentially causing cross-reactivity.

  • Solution: Validate antibody specificity using recombinant expression systems and genetic knockout/knockdown approaches. When possible, complement antibody-based detection with mass spectrometry for unambiguous isoform identification.

• Detection in diverse experimental models:

  • Challenge: MUP1 expression varies significantly between models, potentially falling below detection thresholds in certain conditions.

  • Solution: Optimize protein extraction protocols for specific sample types, consider concentration steps for dilute samples, and adjust exposure times/gain settings for imaging to ensure detection of low abundance protein.

How can researchers optimize MUP1 antibody protocols for specific tissue or cell types?

To optimize MUP1 antibody protocols for specific tissues or cell types, implement these methodological refinements:

• Liver tissue and hepatocytes:

  • As primary sites of MUP1 expression, these samples typically require lower antibody concentrations (5-10 μg/mL) to avoid oversaturation.

  • For immunofluorescence in liver sections, include autofluorescence quenching steps (such as Sudan Black B treatment) to minimize lipofuscin-related background.

  • When isolating primary hepatocytes for in vitro studies, confirm functional MUP1 expression before antibody application using RT-PCR .

• Cell lines (such as NCTC 1469 mouse liver cells):

  • For immunocytochemistry, optimal results have been achieved using 10 μg/mL antibody concentration with 3-hour room temperature incubation .

  • When using cell lines for recombinant MUP1 expression (e.g., HepG2 cells with adenoviral infection), verify expression in both cellular and secreted fractions using Western blotting before conducting downstream applications .

• Metabolic disease models:

  • In diabetic or obese mouse models where MUP1 expression is reduced, increase sample loading for Western blots and extend exposure times.

  • Consider concentrating urine samples through filtration or precipitation methods before antibody application to enhance detection sensitivity.

• Membrane localization studies:

  • When studying MUP1 plasma membrane distributions, combine TIRFM with deconvolution techniques for optimal resolution of membrane microdomains .

  • Use membrane fractionation approaches to biochemically validate microscopy findings regarding MUP1 compartmentalization.

What novel applications of MUP1 antibodies are emerging in metabolic disease research?

Several innovative applications of MUP1 antibodies are emerging in metabolic disease research, opening new investigative avenues:

• Biomarker development for metabolic syndrome:

  • MUP1 expression is significantly downregulated in both genetic and diet-induced obesity models, suggesting its potential as a biomarker for metabolic dysfunction .

  • Antibody-based assays for circulating MUP1 levels could provide a non-invasive approach to monitoring hepatic metabolic health and response to interventions.

• Therapeutic monitoring in experimental treatments:

  • As MUP1 supplementation shows promise in reversing hyperglycemia and improving insulin sensitivity, antibodies can help monitor therapeutic delivery and pharmacokinetics of recombinant MUP1 in experimental models .

  • Quantitative assessment of restored MUP1 levels following experimental therapies can help establish dose-response relationships.

• Multi-parameter tissue analysis:

  • Combining MUP1 antibodies with markers of insulin signaling, gluconeogenesis, and lipid metabolism in multiplexed imaging approaches could reveal spatial relationships between MUP1 expression and metabolic pathway activation.

  • Such approaches could identify specific hepatic zones or cell populations most affected by MUP1 dysregulation.

• Membrane microdomain research:

  • MUP1 antibodies are proving valuable for studying dynamic protein redistribution between membrane compartments, potentially revealing how membrane organization influences metabolic signaling .

  • This application extends beyond metabolism to fundamental cell biology questions regarding compartmentalization of cellular functions.

How might methodological advances improve detection and characterization of MUP1 in research applications?

Emerging methodological advances are poised to enhance MUP1 detection and characterization in various research contexts:

• Super-resolution microscopy techniques:

  • Beyond conventional TIRFM, super-resolution approaches like PALM, STORM, or STED microscopy could provide nanoscale resolution of MUP1 organization within membrane microdomains.

  • These techniques would enable more precise mapping of MUP1 interactions with other membrane components during substrate-induced relocalization events .

• Live-cell biosensors:

  • Development of antibody-derived single-chain variable fragments (scFvs) or nanobodies against MUP1 could enable live-cell imaging of trafficking without fixation artifacts.

  • Combined with FRET-based approaches, such tools could reveal transient protein-protein interactions governing MUP1 function and localization.

• Quantitative proteomics integration:

  • Coupling immunoprecipitation using MUP1 antibodies with mass spectrometry could identify interaction partners under different metabolic conditions.

  • This approach would help construct comprehensive interaction networks explaining how MUP1 influences multiple metabolic pathways simultaneously.

• Single-cell analytical techniques:

  • Antibody-based single-cell analysis could reveal cell-to-cell variability in MUP1 expression and localization within heterogeneous liver tissue.

  • Such approaches would help determine whether specific hepatocyte subpopulations are more responsive to MUP1-mediated metabolic regulation.